Reduction in HIV community viral loads following the implementation of a “Treatment as Prevention” strategy over 2 years at a population-level among men who have sex with men in Hangzhou, China
Tóm tắt
Từ khóa
Tài liệu tham khảo
Cohen MS, Chen YQ, McCauley M, Gamble T, Hosseinipour MC, Kumarasamy N, Hakim JG, Kumwenda J, Grinsztejn B, Pilotto JH, et al. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med. 2011;365(6):493–505.
Kenyon C, Boulle A. Have the explosive HIV epidemics in sub-Saharan Africa been driven by higher community viral load? AIDS. 2013;27(15):2496–7.
Li R, Pan X, Ma Q, Wang H, He L, Jiang T, Wang D, Zhang Y, Zhang X, Xia S. Prevalence of prior HIV testing and associated factors among MSM in Zhejiang Province, China: a cross-sectional study. BMC Public Health. 2016;16(1):1152.
Mindel A, Sawleshwarkar S. Condoms for sexually transmissible infection prevention: politics versus science. Sex Health. 2008;5(1):1–8.
Baggaley RF, Boily MC, White RG, Alary M. Risk of HIV-1 transmission for parenteral exposure and blood transfusion: a systematic review and meta-analysis. AIDS. 2006;20(6):805–12.
Das M, Chu PL, Santos GM, Scheer S, Vittinghoff E, McFarland W, Colfax GN. Decreases in community viral load are accompanied by reductions in new HIV infections in San Francisco. PLoS One. 2010;5(6):e11068.
Miller WC, Powers KA, Smith MK, Cohen MS. Community viral load as a measure for assessment of HIV treatment as prevention. Lancet Infect Dis. 2013;13(5):459–64.
Laraque F, Mavronicolas HA, Robertson MM, Gortakowski HW, Terzian AS. Disparities in community viral load among HIV-infected persons in new York City. AIDS. 2013;27(13):2129–39.
Solomon SS, Mehta SH, McFall AM, Srikrishnan AK, Saravanan S, Laeyendecker O, Balakrishnan P, Celentano DD, Solomon S, Lucas GM. Community viral load, antiretroviral therapy coverage, and HIV incidence in India: a cross-sectional, comparative study. Lancet HIV. 2016;3(4):e183–90.
Castel AD, Befus M, Willis S, Griffin A, West T, Hader S, Greenberg AE. Use of the community viral load as a population-based biomarker of HIV burden. AIDS. 2012;26(3):345–53.
Henard S, Jeanmaire E, Nguyen Y, Yazdanpanah Y, Cheret A, Hoen B, Rey D, Borel A, Chavanet P, May T, et al. Is total community viral load a robust predictive marker of the efficacy of the TasP strategy? J Acquir Immune Defic Syndr. 2012;61(3):400–2.
Tilghman MW, Perez-Santiago J, Osorio G, Little SJ, Richman DD, Mathews WC, Haubrich RH, Smith DM. Community HIV-1 drug resistance is associated with transmitted drug resistance. HIV Med. 2014;15(6):339–46.
Wood E, Kerr T, Marshall BD, Li K, Zhang R, Hogg RS, Harrigan PR, Montaner JS. Longitudinal community plasma HIV-1 RNA concentrations and incidence of HIV-1 among injecting drug users: prospective cohort study. BMJ. 2009;338:b1649.
Liotta G, Chimbwandira F, Wouters K, Nielsen-Saines K, Jere H, Mancinelli S, Ceffa S, Erba F, Palombi L, Marazzi MC. Impact of extended combination antiretroviral therapy on the decline of HIV prevalence in pregnant women in Malawi. J Int Assoc Provid AIDS Care. 2016;15(2):172–7.
Chakraborty H, Weissman S, Duffus WA, Hossain A, Varma SA, Iyer M, Albrecht H. HIV community viral load trends in South Carolina. Int J STD AIDS. 2017;28(3):265–76.
Kelley CF, Rosenberg ES, O'Hara BM, Frew PM, Sanchez T, Peterson JL, Del RC SPS, et al. PLoS One. 2012;7(12):e53284.
Montaner JS, Lima VD, Barrios R, Yip B, Wood E, Kerr T, Shannon K, Harrigan PR, Hogg RS, Daly P, et al. Association of highly active antiretroviral therapy coverage, population viral load, and yearly new HIV diagnoses in British Columbia, Canada: a population-based study. Lancet. 2010;376(9740):532–9.
Herbeck JT, Mittler JE, Gottlieb GS, Mullins JI. An HIV epidemic model based on viral load dynamics: value in assessing empirical trends in HIV virulence and community viral load. PLoS Comput Biol. 2014;10(6):e1003673.
Krentz HB, Gill MJ. The effect of churn on “community viral load” in a well-defined regional population. J Acquir Immune Defic Syndr. 2013;64(2):190–6.
Law MG, Woolley I, Templeton DJ, Roth N, Chuah J, Mulhall B, Canavan P, McManus H, Cooper DA, Petoumenos K. Trends in detectable viral load by calendar year in the Australian HIV observational database. J Int AIDS Soc. 2011;14:10.
http://ncaids.chinacdc.cn/fzdt/zxdd/201703/t20170316_139120.htm , 2017.
Pan X, Wu M, Ma Q, Wang H, Ma W, Zeng S, Chen J, Zhang Y, Miao D, Zhou X, et al. High prevalence of HIV among men who have sex with men in Zhejiang, China: a respondent-driven sampling survey. BMJ Open. 2015;5(12):e8466.
Zhang F, Dou Z, Ma Y, Zhang Y, Zhao Y, Zhao D, Zhou S, Bulterys M, Zhu H, Chen RY. Effect of earlier initiation of antiretroviral treatment and increased treatment coverage on HIV-related mortality in China: a national observational cohort study. Lancet Infect Dis. 2011;11(7):516–24.
He L, Pan X, Dou Z, Huang P, Zhou X, Peng Z, Zheng J, Zhang J, Yang J, Xu Y, et al. The factors related to CD4+ T-cell recovery and viral suppression in patients who have low CD4+ T cell counts at the initiation of HAART: a retrospective study of the national HIV treatment sub-database of Zhejiang Province, China, 2014. PLoS One. 2016;11(2):e148915.
Fauci AS, Pantaleo G, Stanley S, Weissman D. Immunopathogenic mechanisms of HIV infection. Ann Intern Med. 1996;124(7):654–63.
Graham JW. Missing data analysis: making it work in the real world. Annu Rev Psychol. 2009;60:549–76.
Hanna DB, Felsen UR, Ginsberg MS, Zingman BS, Beil RS, Futterman DC, Strickler HD, Anastos K. Increased antiretroviral therapy use and Virologic suppression in the Bronx in the context of multiple HIV prevention strategies. AIDS Res Hum Retrovir. 2016;32(10–11):955–63.
Touzard RF, Gillani FS, Ackerman P, Rana A, Kojic EM, Beckwith CG. Monitored viral load: a measure of HIV treatment outcomes in an outpatient setting in Rhode Island. R I Med J (2013). 2014;98(1):26–30.
Granich R, Kahn JG, Bennett R, Holmes CB, Garg N, Serenata C, Sabin ML, Makhlouf-Obermeyer C, De Filippo MC, Williams P, et al. Expanding ART for treatment and prevention of HIV in South Africa: estimated cost and cost-effectiveness 2011-2050. PLoS One. 2012;7(2):e30216.
Eaton JW, Johnson LF, Salomon JA, Barnighausen T, Bendavid E, Bershteyn A, Bloom DE, Cambiano V, Fraser C, Hontelez JA, et al. HIV treatment as prevention: systematic comparison of mathematical models of the potential impact of antiretroviral therapy on HIV incidence in South Africa. PLoS Med. 2012;9(7):e1001245.
Tanser F, Barnighausen T, Grapsa E, Zaidi J, Newell ML. High coverage of ART associated with decline in risk of HIV acquisition in rural KwaZulu-Natal, South Africa. Science. 2013;339(6122):966–71.
Smith MK, Powers KA, Muessig KE, Miller WC, Cohen MS. HIV treatment as prevention: the utility and limitations of ecological observation. PLoS Med. 2012;9(7):e1001260.
Moore DM, Cui Z, Lachowsky N, Raymond HF, Roth E, Rich A, Sereda P, Howard T, McFarland W, Lal A, et al. HIV community viral load and factors associated with elevated Viremia among a community-based sample of men who have sex with men in Vancouver, Canada. J Acquir Immune Defic Syndr. 2016;72(1):87–95.
Abu-Raddad LJ, Barnabas RV, Janes H, Weiss HA, Kublin JG, Longini IJ, Wasserheit JN. Have the explosive HIV epidemics in sub-Saharan Africa been driven by higher community viral load? AIDS. 2013;27:981–9.
Kranzer K, Lawn SD, Johnson LF, Bekker LG, Wood R. Community viral load and CD4 count distribution among people living with HIV in a south African township: implications for treatment as prevention. J Acquir Immune Defic Syndr. 2013;63(4):498–505.
Das M, Raymond HF, Chu P, Nieves-Rivera I, Pandori M, Louie B, Rauch L, Scheer S, Vittinghoff E, McFarland W. Measuring the unknown: calculating community viral load among HIV-infected MSM unaware of their HIV status in San Francisco from national HIV behavioral surveillance, 2004-2011. J Acquir Immune Defic Syndr. 2013;63(2):e84–6.
Jain V, Liegler T, Kabami J, Chamie G, Clark TD, Black D, Geng EH, Kwarisiima D, Wong JK, Abdel-Mohsen M, et al. Assessment of population-based HIV RNA levels in a rural east African setting using a fingerprick-based blood collection method. Clin Infect Dis. 2013;56(4):598–605.
Laeyendecker O, Redd AD, Lutalo T, Gray RH, Wawer M, Ssempijja V, Gamiel J, Bwanika JB, Makumbi F, Nalugoda F, et al. Frequency of long-term nonprogressors in HIV-1 seroconverters from Rakai Uganda. J Acquir Immune Defic Syndr. 2009;52(3):316–9.